Semaglutide / Tirzepatide
Both are studied in metabolic settings, but they act on different receptors. This comparison begins with the mechanisms and links to the profiles for findings in context.
The points below summarize the two editorial profiles. Studies, formulations and doses are not interchangeable; open each profile for detail and sources.
Semaglutide
Tirzepatide
Weight and metabolism
Weight and metabolism
Semaglutide is a GLP-1 receptor agonist that affects appetite, satiety, and blood glucose regulation.
Tirzepatide acts at GIP and GLP-1 receptors involved in blood glucose and appetite regulation.
This profile separates data from studied medicines and clinical trials from calculations for generic vials.
The profile helps readers separate clinical outcomes from nominal vial contents.
Clinical programs examine weight management and other metabolic outcomes in defined populations.
Clinical programs have assessed weight and type 2 diabetes outcomes.
The indication, formulation, and product documentation determine whether clinical findings apply.
Documented efficacy concerns studied products and indications; it does not automatically validate different preparations.
This comparison does not suggest which compound to use and is not medical advice. Information refers to the settings described in the respective profiles.